Skip to main content
. 2020 Sep 1;70(4):743–760. doi: 10.1136/gutjnl-2019-319970

Figure 2.

Figure 2

ATM-deficient tumour growth control on PAD treatment. (A) Schematic representation of the subcutaneous assay shown in (B) with treatment administration schedule.(B) Time-dependent development (over the course of 17 days) of subcutaneously engrafted tumours arising either from Atm+/+; LSL-KrasG12D/+; Ptf1aCre/+ (KC) and Atmfl/fl; LSL-KrasG12D/+; Ptf1aCre/+ (AKC) cells (respectively, black circle and red square) treated or not (respectively, dashed lines and solid lines) with a combination of olaparib (50 mg/kg), VE-822 (20 mg/kg) and, CC-115 (2.5 mg/kg) (PAD, PARPi/ATRi/DNA-PKi), with representative macroscopic images. Scale bars represent 5 mm. (C) Quantification of tumour weight of resected tumours from subcutaneous assay shown in (B). (D) Immunohistochemistry staining for H2AX p-S139 and cleaved caspase-3 (CC3) and (E) quantifications of H2AX p-S139-positive cells and (F) of CC3-positive surface in resected tumours from subcutaneous assay shown in (B). Scale bars represent 100 µm. Veh, vehicle. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.